Hansen Medical Announces Changes to Its Board of Directors

Hansen Medical Announces Changes to Its Board of Directors 
MOUNTAIN VIEW, CA -- (Marketwire) -- 12/12/12 --  Hansen Medical,
Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today
announced changes to its Board of Directors. These changes include
the appointment of Michael Eagle, a current director, as Chairman of
the Board and the resignations of Russell C. Hirsch, M.D., Ph.D., and
James M. Shapiro. Mr. Eagle replaces Dr. Hirsch as the Company's lead
outside director. In addition, Stephen L. Newman, M.D., also a
current director, has been appointed to replace Mr. Eagle as Chair of
the Board's Nominating and Corporate Governance Committee.  
"I am appreciative of the Board's confidence and pleased to have been
appointed Chairman of the Board at such a critical juncture for the
Company," said Mr. Eagle. "As Hansen Medical's business evolves to a
commercial and operational focus, our current Board structure is
reflective of this evolution, as evidenced by the director
appointments of Mr. Bill Rohn, Dr. Steve Newman, Mr. Nadim Yared, and
me earlier this year. On behalf of the entire Board, I would like to
thank both Russell and Jim for their level of commitment during the
last 10 and eight years, respectively, that each of them served on
the Board." 
"The Board currently consists of seven directors, six of whom are
independent," continued Mr. Eagle. "We intend to appoint an eighth
director in the coming months."  
"Since being appointed to the Board in February, Mike's operational
and commercial expertise have been enormous assets to the Company as
we prepared for and executed the launch of our Magellan(TM) Robotic
System," said Bruce Barclay, Hansen Medical's President and Chief
Executive Officer. "We look forward to his continued significant
contributions in his new role as Chairman. Simultaneously, I'd also
like to thank Russell and Jim for the critical guidance and multiple
contributions both provided Hansen Medical during their long tenures
on the Board." 
Mr. Eagle, who was appointed to the Board in February 2012, has a
substantial history of operational, commercial and manufacturing
experience in both the medical technology and pharmaceutical
industries. He has held various leadership positions at a number of
notable healt
hcare companies, including Eli Lilly and Company,
Advanced Cardiovascular Systems, IVAC Corporation, and IMED
Corporation. Since retiring from his most recent position of Vice
President of Global Manufacturing for Lilly in 2001, he has served as
a founding member of Barnard Life Sciences, LLC, a healthcare
consulting company. Additionally, Mr. Eagle has served as a director
on a number of boards of both public and private healthcare
companies, including Favrille Inc., Micrus Endovascular, Inc. and
Perclose, Inc. He currently serves on the boards of Cadence
Pharmaceuticals and Somaxon Pharmaceuticals. 
About Hansen Medical, Inc. 
 Hansen Medical, Inc., based in Mountain
View, California, is a global leader in intravascular robotics,
developing products and technology designed to enable the accurate
positioning, manipulation and control of catheters and catheter-based
technologies. The Company's Magellan(TM) Robotic System,
NorthStar(TM) Robotic Catheter and related accessories, which are
intended to facilitate navigation to anatomical targets in the
peripheral vasculature and subsequently provide a conduit for manual
placement of therapeutic devices, have undergone both CE marking and
510(k) clearance and are commercially available in the European
Union, and the U.S. In the European Union, the Company's Sensei(R) X
Robotic Catheter System and Artisan Control Catheter are cleared for
use during electrophysiology (EP) procedures, such as guiding
catheters in the treatment of atrial fibrillation (AF), and the
Lynx(R) Robotic Ablation Catheter is cleared for the treatment of AF.
This robotic catheter system is compatible with fluoroscopy,
ultrasound, 3D surface map and patient electrocardiogram data. In the
U.S. the Company's Sensei X Robotic Catheter System and Artisan
Control Catheter were cleared by the U.S. Food and Drug
Administration for manipulation and control of certain mapping
catheters in EP procedures. In the United States, the Sensei System
is not approved for use in guiding ablation procedures; this use
remains experimental. The U.S. product labeling therefore provides
that the safety and effectiveness of the Sensei X System and Artisan
Control Catheter for use with cardiac ablation catheters in the
treatment of cardiac arrhythmias, including AF, have not been
established. Additional information can be found at
Forward-Looking Statements
 This press release contains
forward-looking statements regarding, among other things, statements
relating to goals, plans, objectives, milestones and future events.
All statements, other than statements of historical fact, are
statements that could be deemed forward-looking statements, including
statements containing the words "plan," "expects," "potential,"
"believes," "goal," "estimate," "anticipates," and similar words.
These statements are based on the current estimates and assumptions
of our management as of the date of this press release and are
subject to risks, uncertainties, changes in circumstances and other
factors that may cause actual results to differ materially from the
information expressed or implied by forward-looking statements made
in this press release. Examples of such statements include statements
about the potential benefits of our technology and the value of our
intellectual property portfolio. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, among others: engineering,
regulatory, manufacturing, sales and customer service challenges in
developing new products and entering new markets; potential safety
and regulatory issues that could slow or suspend our sales; the
effect of credit, financial and economic conditions on capital
spending by our potential customers; the uncertain timelines for the
sales cycle for newly introduced products; the rate of adoption of
our systems and the rate of use of our catheters; the scope and
validity of intellectual property rights applicable to our products;
competition from other companies; our ability to recruit and retain
key personnel; our ability to maintain our remedial actions over
previously reported material weaknesses in internal controls over
financial reporting; our ability 
to manage expenses and cash flow,
and obtain additional financing; and other risks more fully described
in the "Risk Factors" section of our Quarterly Report on Form 10-Q
for the quarter ended September 30, 2012 filed with the SEC on
November 9, 2012 and the risks discussed in our other reports filed
with the SEC. Given these uncertainties, you should not place undue
reliance on the forward-looking statements in this press release. We
undertake no obligation to revise or update information herein to
reflect events or circumstances in the future, even if new
information becomes available.  
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan and
NorthStar are trademarks of Hansen Medical, Inc. in the United States
and other countries. 
Investor Contacts: 
Peter J. Mariani 
Chief Financial Officer 
Hansen Medical, Inc. 
FTI Consulting, Inc.
Brian Ritchie
John Capodanno
Press spacebar to pause and continue. Press esc to stop.